Step 1: Understanding the Concept:
Incretin hormones such as GLP-1 are released from the gut after eating and help the pancreas release insulin, but they are broken down quickly by the enzyme dipeptidyl peptidase-4 (DPP-4). Blocking this enzyme keeps incretin levels higher for longer.
Step 2: Key Formula or Approach:
Among oral hypoglycemic drug classes, gliptins (DPP-4 inhibitors) are the group built specifically to block this enzyme, while biguanides (metformin), thiazolidinediones (pioglitazone), and sulfonylureas (glipizide) work through entirely different pathways.
Step 3: Detailed Explanation:
Sitagliptin belongs to the gliptin class and binds to the DPP-4 enzyme, stopping it from degrading GLP-1 and GIP. This raises the amount of active incretin hormone circulating after a meal, which increases glucose-dependent insulin secretion from the pancreas and reduces glucagon release from the liver, together lowering blood glucose. Metformin, pioglitazone, and glipizide each act on different targets (liver glucose output, PPAR-gamma receptors, and pancreatic potassium channels respectively) and do not touch DPP-4.
Step 4: Final Answer:
Sitagliptin is the oral hypoglycemic agent that raises incretin hormone levels by inhibiting DPP-4.